Daniel Soteres
YOU?
Author Swipe
View article: Long-Term Prophylactic Treatment Preferences and Willingness to Switch Therapy in Individuals With Hereditary Angioedema
Long-Term Prophylactic Treatment Preferences and Willingness to Switch Therapy in Individuals With Hereditary Angioedema Open
Effectiveness was the main driver of LTP preference; other factors were also important, including convenience. When effectiveness was equivalent, oral administration was preferred over injectable administration. Individuals with HAE were m…
View article: Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐S
Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐S Open
Background Hereditary angioedema (HAE‐C1INH) attacks involving mucosal tissue may progress rapidly and often lead to substantial morbidity. Severe laryngeal attacks can be fatal without prompt administration of on‐demand treatment. This pr…
View article: Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years
Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years Open
Introduction: Hereditary angioedema (HAE) is a rare genetic disorder characterized by unpredictable, painful swelling attacks that significantly impair patients’ quality of life (QoL). Clinical trials of lanadelumab led to its approval for…
View article: Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study Open
ClinicalTrials.gov, identifier NCT03845400. Graphical abstract available for this article.
View article: Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines
Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelines Open
Over the past 2 decades, guidelines for the on-demand treatment of hereditary angioedema attacks have undergone significant evolution. Early treatment guidelines, such as the Canadian 2003 International Consensus Algorithm, often gated on-…
View article: Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis
Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis Open
Background: Hereditary angioedema (HAE) is a rare genetic disorder characterized by painful, debilitating, and potentially fatal swelling attacks. Lanadelumab is approved as long-term prophylaxis (LTP) in patients with HAE. However, real-w…
View article: Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study
Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study Open
Background: Hereditary angioedema (HAE) is a rare genetic condition characterized by painful and often debilitating swelling attacks. Little is known about the differences in outcomes between patients with HAE types I or II (type I: HAE ca…
View article: Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks Open
Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo. (Funded by KalVista Pharmaceuticals; KONFIDENT ClinicalTrials.gov number, NCT05259917; E…
View article: Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial Open
Berotralstat was generally well tolerated, provided rapid and sustained reductions in HAE attacks and improved QoL over 96 weeks.
View article: Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape Open
This report describes the successful transition of two familial patients with HAE from injectable to oral prophylaxis without tapering prior therapy or employing a complex transition protocol.
View article: Optimization of care for patients with hereditary angioedema living in rural areas
Optimization of care for patients with hereditary angioedema living in rural areas Open
For patients with HAE living in rural areas, optimal care is complicated by health disparities. Given the scarcity with which these topics have been covered in the literature to date, it is intended that this article will serve as the impe…
View article: Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension
Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension Open
For induction full responders, continuing BOS numerically improved maintenance of efficacy vs withdrawal. A longer therapy duration did not raise safety concerns. (ClinicalTrials.gov: NCT02736409.).
View article: A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema Open
Background Patients with hereditary angioedema with C1 inhibitor deficiency or dysfunction have burdensome recurrent angioedema attacks. The safety, efficacy, and health‐related quality of life (HRQoL) outcomes of C1 inhibitor (C1‐INH) pro…
View article: Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study
Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study Open
Fixed-dose subcutaneous pdC1-INH liquid was superior to placebo in preventing HAE attacks and demonstrated a favorable safety profile.
View article: Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks Open
EudraCT Identifier: 2015-003943-20; ClinicalTrials.gov Identifier: NCT02586805.
View article: NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps
NAVIGATE I: Randomized, Placebo-Controlled, Double-Blind Trial of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis With Nasal Polyps Open
Background Chronic rhinosinusitis is a common, high-morbidity chronic inflammatory disease, and patients often experience suboptimal outcomes with current medical treatment. The exhalation delivery system with fluticasone (EDS-FLU) may imp…
View article: Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp>‐2 study
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <span>OPuS</span>‐2 study Open
Background Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐ INH ‐ HAE ) by reducing the frequency of angioedema attacks. Avoralstat is a …